Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
12
Not yet recruiting, industry sponsors, Pain and anesthesia, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed433
12 trials
Showing 1 to 12, recently updated first.
- A Study to Assess IG001643 in Healthy ParticipantsNot yet recruiting
Iongen Therapeutics Co., Ltd.Industry
NCT07924397 · 86 participants (planned) · Start Nov 10, 2026 · Primary completion May 16, 2027
Drug: IG001643; Placebo · For: Pain Management
Sites: Christchurch, New Zealand
- Phase I Study of JY1001 InjectionNot yet recruiting
JemincareIndustry
NCT07848945 · 48 participants (planned) · Start Nov 2026 · Primary completion May 2027
Drug: JY1001; Placebo · For: Pain After Surgery
Sites: Chengdu, China
- Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc DiseaseNot yet recruiting
Kolon TissueGene, Inc.Industry
NCT06144970 · 24 participants (planned) · Start Jan 19, 2027 · Primary completion Jul 28, 2028
Drug: TG-C High Dose; TG-C Mid Dose and 2 more · For: Degenerative Disc Disease
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone MetastasesNot yet recruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07731685 · 26 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 30, 2027
Drug: VC004 low dose; VC004 high dose and 1 more · For: Pain in Bone Metastases
Sites: Nanjing, China · 2 sites in all
- A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerNot yet recruiting
Glycyx TherapeuticsIndustry
NCT07662720 · 18 participants (planned) · Start Jul 15, 2026 · Primary completion Aug 31, 2027
Drug: axelopran; Pembolizumab · For: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Intradiscal rhGDF-6 for the Treatment of Lumbar Disc DegenerationNot yet recruiting
Cartago Biotech Pty LtdIndustry
NCT07668466 · 60 participants (planned) · Start Jul 4, 2026 · Primary completion Aug 31, 2028
Drug: High Dose; Low Dose · For: Disc Degenerative Disease; Back Pain
Sites: Kogarah, Australia
- Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy ParticipantsNot yet recruiting
Neurodawn Pharmaceutical Co., Ltd.Industry
NCT07618715 · 11 participants (planned) · Start Jun 30, 2026 · Primary completion Aug 31, 2026
Drug: Y-4 tablet; Pregabalin capsule and 1 more · For: Healthy Male and Female Subjects
Sites: Secaucus, New Jersey
- The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee OsteoarthritisNot yet recruiting
TricelX Inc.Industry
NCT07487766 · 75 participants (planned) · Start May 2026 · Primary completion May 2027
Drug: Mesenchymal Stem Cell Injection · For: Osteoarthritis
Sites: Frisco, Texas
- ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back PainNot yet recruiting
Interventional AnalgesiX Inc.Industry
NCT07520240 · 32 participants (planned) · Start Jun 1, 2026 · Primary completion Jan 31, 2027
Drug: ITX24-01; Normal Saline (0.9% NaCl) · For: Facet Joint Pain
Sites: Wahroonga, Australia
- Efficacy and Safety of KHN702 Tablets in Moderate to Severe Post-operative Pain SubjectsNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07277933 · 24 participants (planned) · Start Dec 2025 · Primary completion Feb 2026
Drug: KHN702; KHN702 placebo · For: Postoperative Pain
- A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain ManagementNot yet recruiting
HillMed Inc.Industry
NCT05062902 · 46 participants (planned) · Start Sep 15, 2025 · Primary completion Aug 15, 2027
Drug: Botulinum Neurotoxin · For: Interstitial Cystitis; Chronic Pain; Pelvic Floor; Relaxation and 1 more
Sites: Houston, Texas
- Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic InsomniaNot yet recruiting
Nyree PennIndustry
NCT06644573 · 100 participants (planned) · Start Nov 1, 2025 · Primary completion May 1, 2026
Drug: Diprivan (propofol), Astra-Zeneca · For: Chronic Insomnia; Sleep Deprivation; REM Behavior Disorder and 34 more
Sites: Aventura, Florida
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.